First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer
PHASE2
This phase II study focuses on women with rapidly progressive hormone recep...
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
N/A
This non-interventional observational study evaluates the real-world effect...
A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients
N/A
The aim of this study was to assess real-world treatment patterns and toler...
Status
Completed
Location
Novartis
Start Date
2025-02-26
Trial ID
NCT07760714
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia
N/A
This is а prospective, non-interventional, primary data collection cohort s...